Evidence map›Paper›PMID 27272773›Full record

ArticleAnticancer research2016

Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.

Dong-Joon Min, Siping He, Jeffrey E Green

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Anticancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Targeting Apoptosis in Cancer.Current oncology reports · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dong-Joon MinTransgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Siping HeTransgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A.
Jeffrey E GreenTransgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A. jegreen@nih.gov.
National Cancer Institute · US

Funding

Transgenic Models for Prostate and Breast CancerZIABC005740 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GREEN, JEFFREY E · 2009 to 2016
$7.8M
TRANSGENIC MODELS FOR PROSTATE AND BREAST CANCERZ01BC005740 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GREEN, JEFFREY E · 1996 to 2008
$4.2M
Intramural NIH HHS Z01 BC005740
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is an aggressive form of breast cancer currently lacking targeted therapies. Our previous work demonstrated a therapeutic synergism with gemcitabine (GEM) and the CHK1 inhibitor (AZD7762) combination treatment in a TNBC cell line. We hypothesized that the response to this combination therapy would differ among heterogeneous TNBC patients and that addition of a SMAC mimetic (TL32711) could improve efficacy. MATERIALS AND

methodsTherapeutic responses to GEM, GEM/AZD7762, and GEM/AZD7762/TL32711 combinations were investigated by XTT assays and western blotting of cell cycle and apoptosis-related proteins in ten TNBC cell lines.

resultsTNBC cell lines harboring low levels of endogenous CHK1, cIAP1 and cIAP2 were responsive to GEM alone, whereas cell lines demonstrating a minimal increase in phospho-S345 CHK1 after treatment were responsive to GEM/AZD7762 or GEM/AZD7762/TL32711 combination.

conclusionThe response of TNBC cells to particular therapies varies and will require development of predictive biomarkers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCheckpoint Kinase 1DeoxycytidineDipeptidesDNA RepairFemaleGemcitabineHumansIndolesPhosphorylationThiophenesTriple Negative Breast NeoplasmsUrea3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamidebirinapantCheckpoint Kinase 1CHEK1 protein, humanDeoxycytidineDipeptidesGemcitabineIndolesThiophenesUreaCHK1Combination treatmentTL32711triple-negative breast cancer

Identifiers

PMID27272773
PMCPMC6953430
OpenAlexW2417664297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.